WJA
CMTA

Williams Jones & Associates’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Williams Jones & Associates’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,100
Closed -$133K – 470
2018
Q2 		$133K Buy
+10,100
New +$164K ﹤0.01% 420

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Williams Jones & Associates's CMTA Position: Q3 2018 in Review

Williams Jones & Associates sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q3 2018, closing a stake of 10,100 shares — an estimated $133K sold.

Williams Jones & Associates first reported a position in CMTA in Q2 2018 and held it in 1 quarter. The position peaked at $133K in Q2 2018. 27 funds tracked by Wall St. Rank hold CMTA as of Q3 2018.

  • Williams Jones & Associates reported no remaining Clementia Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • Williams Jones & Associates sold 10,100 Clementia Pharmaceuticals Inc. shares in Q3 2018, an estimated $133K.
  • Williams Jones & Associates first reported a position in Clementia Pharmaceuticals Inc. in Q2 2018 and held it in 1 quarter.
  • Williams Jones & Associates's Clementia Pharmaceuticals Inc. position peaked at $133K in Q2 2018.
  • 27 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q3 2018.

Based on Williams Jones & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.